Pharmaceuticals, Biotechnology and Life Sciences
Sanofi and Hanmi Pharmaceutical Co., Ltd. announced Thursday a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments.
Redx, the drug discovery and development company, has made two senior management appointments.
The company on Thursday said that Nicholas Adams is new as Chief Business Officer and Dr Matilda Bingham has been promoted to Executive Director of Redx Oncology Ltd, the Group’s oncology subsidiary.
Verona Pharma has completed patient enrolment for the Phase IIa dose-finding study of RPL554 in asthma and the Phase IIa combination study of RPL554 in chronic obstructive pulmonary disease (COPD), in which the drug is being administered in addition to standard of care bronchodilators.
ViiV Healthcare, a global specialist HIV company with GSK (GlaxoSmithKline), Pfizer Inc. and Shionogi Limited as shareholders, announced on Tuesday that the Phase IIb study LATTE 2 (NCT02120352) met its primary endpoint at 32 weeks.
Nearly all later entrants to drug classes had begun clinical testing or were in regulatory review in the United States before the first drug within a pharmacologic class was approved, a newly completed analysis from the Tufts Center for the Study of Drug Development suggests.
Janssen-Cilag International NV announced on Tuesday the submission of a Type II variation application to the European Medicines Agency (EMA) seeking…
OptiBiotix Health has announced the filing of two new patents covering its cholesterol reducing product. This increases the number of patents from nine to eleven.
Finland’s Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company, has entered into an agreement with Swiss-based Selexis SA for producing Novel Cancer Immunotherapy Clevegen.
Sanofi and BioNTech A.G. have entered into a multiyear exclusive collaboration and license agreement.
Bayer CropScience has reached an important milestone towards the market introduction of its innovative insecticide Sivanto prime in Europe.